Affordable Access

deepdyve-link
Publisher Website

Excessive Weight Gain Before and During Gestational Diabetes Mellitus Management: What Is the Impact?

Authors
  • Barnes, Robyn A1, 2
  • Wong, Tang3, 4, 5
  • Ross, Glynis P3, 5
  • Griffiths, Michelle M3
  • Smart, Carmel E2, 6
  • Collins, Clare E2, 7
  • MacDonald-Wicks, Lesley2, 7
  • Flack, Jeff R3, 4, 8
  • 1 Diabetes Centre, Bankstown-Lidcombe Hospital, NSW, Australia [email protected] , (Australia)
  • 2 School of Health Sciences, Faculty of Health and Medicine, University of Newcastle, Callaghan, NSW, Australia. , (Australia)
  • 3 Diabetes Centre, Bankstown-Lidcombe Hospital, NSW, Australia. , (Australia)
  • 4 Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia. , (Australia)
  • 5 Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia. , (Australia)
  • 6 Department of Paediatric Endocrinology and Diabetes, John Hunter Children's Hospital, Newcastle, NSW, Australia. , (Australia)
  • 7 Priority Research Centre in Physical Activity and Nutrition, University of Newcastle, Callaghan, NSW, Australia. , (Australia)
  • 8 School of Medicine, Western Sydney University, Sydney, NSW, Australia. , (Australia)
Type
Published Article
Journal
Diabetes care
Publication Date
Nov 05, 2019
Identifiers
DOI: 10.2337/dc19-0800
PMID: 31690637
Source
Medline
Language
English
License
Unknown

Abstract

Conventional gestational diabetes mellitus (GDM) management focuses on managing blood glucose in order to prevent adverse outcomes. We hypothesized that excessive weight gain at first presentation with GDM (excessive gestational weight gain [EGWG]) and continued EGWG (cEGWG) after commencing GDM management would increase the risk of adverse outcomes, despite treatment to optimize glycemia. Data collected prospectively from pregnant women with GDM at a single institution were analyzed. GDM was diagnosed on the basis of Australasian Diabetes in Pregnancy Society 1998 guidelines (1992-2015). EGWG means having exceeded the upper limit of the Institute of Medicine recommended target ranges for the entire pregnancy, by GDM presentation. The relationship between EGWG and antenatal 75-g oral glucose tolerance test (oGTT) values, and adverse outcomes, was evaluated. Relationships were examined between cEGWG, insulin requirements, and large-for-gestational-age (LGA) infants. Of 3,281 pregnant women, 776 (23.6%) had EGWG. Women with EGWG had higher mean fasting plasma glucose (FPG) on oGTT (5.2 mmol/L [95% CI, 5.1-5.3] vs. 5.0 mmol/L [95% CI, 4.9-5.0]; P < 0.01), after adjusting for confounders, and more often received insulin therapy (47.0 vs. 33.6%; P < 0.0001), with an adjusted odds ratio (aOR) of 1.4 (95% CI, 1.1-1.7; P < 0.01). aORs for each 2-kg increment of cEGWG were a 1.3-fold higher use of insulin therapy (95% CI, 1.1-1.5; P < 0.001), an 8-unit increase in final daily insulin dose (95% CI, 5.4-11.0; P < 0.0001), and a 1.4-fold increase in the rate of delivery of LGA infants (95% CI, 1.2-1.7; P < 0.0001). The absence of EGWG and restricting cEGWG in GDM have a mitigating effect on oGTT-based FPG, the risk of having an LGA infant, and insulin requirements. © 2019 by the American Diabetes Association.

Report this publication

Statistics

Seen <100 times